Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we’re talking about! Here is some more information if you’re curious.
Welcome to another edition of “3 Things In Biotech,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Mallinckrodt’s jaundice drug rejected by the FDA
Company: Mallinckrodt (NYSE:MNK)
Therapy: Stannsoporfin
Disease: Severe jaundice
News: MNK announced....More>>>